Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis
View abstract on PubMed
Summary
This summary is machine-generated.Tumor expression of peroxisome proliferator-activated receptor gamma (PPARG) is linked to better survival in colon cancer patients. PPARG-positive tumors indicate a less aggressive cancer subset, suggesting a favorable prognosis.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Peroxisome proliferator-activated receptor gamma (PPARG) regulates lipid metabolism and inflammation.
- PPARG's role in colon cancer is debated, with unclear prognostic significance.
Purpose Of The Study
- To investigate the prognostic value of PPARG expression in colorectal cancer patients.
- To determine if PPARG expression correlates with patient survival and cancer aggressiveness.
Main Methods
- Immunohistochemistry detected PPARG in 22% of 470 colorectal cancer tumors (Stages I-IV).
- Cox proportional hazards models analyzed mortality risks, adjusting for clinical and molecular features (e.g., MSI, CIMP, KRAS).
Main Results
- PPARG-positive tumors were associated with significantly lower overall mortality (adjusted HR, 0.43; P=.0004).
- Colorectal cancer-specific mortality was also lower in patients with PPARG-positive tumors (adjusted HR, 0.44; P=.0054).
- PPARG's prognostic effect was independent of other molecular markers.
Conclusions
- Tumor PPARG expression independently predicts longer survival in colorectal cancer patients.
- PPARG expression may identify an indolent subtype of colorectal cancer.